Searched over 200M research papers
10 papers analyzed
These studies suggest that high LDL cholesterol is associated with increased risks of peripheral arterial disease, chronic kidney disease, and coronary heart disease, and that lowering LDL levels can improve clinical outcomes and reduce cardiovascular risk.
20 papers analyzed
Low-density lipoprotein cholesterol (LDL-C) is often referred to as "bad cholesterol" due to its association with an increased risk of cardiovascular diseases (CVD). Elevated levels of LDL-C can lead to the development of atherosclerosis, a condition characterized by the buildup of cholesterol and other substances in the arterial walls, which can result in heart attacks and strokes .
High LDL-C is a well-established risk factor for coronary artery disease (CAD). Studies have shown that reducing LDL-C levels can significantly decrease the risk of coronary events and promote the regression of atherosclerosis . Statin therapy, which lowers LDL-C, has been particularly effective in reducing the incidence of heart attacks and other coronary events .
Recent research has extended the understanding of LDL-C's impact beyond coronary arteries to peripheral vascular diseases. High LDL-C levels have been linked to an increased risk of peripheral arterial disease (PAD) and chronic kidney disease (CKD). Observational and genetic analyses indicate that higher LDL-C levels are associated with a higher risk of these conditions, suggesting a causal relationship.
Dietary cholesterol intake has a direct impact on circulating LDL-C levels. Meta-regression analyses have demonstrated that increases in dietary cholesterol lead to corresponding increases in LDL-C concentrations. This relationship is influenced by the intake of saturated and trans fatty acids, which also contribute to elevated LDL-C levels.
Interestingly, the effect of dietary cholesterol on HDL-C (high-density lipoprotein cholesterol) varies between men and women. While dietary cholesterol tends to decrease HDL-C in men, it has the opposite effect in women, highlighting the complexity of cholesterol metabolism and its impact on cardiovascular risk.
Elevated serum uric acid (SUA) levels have been identified as a predictor for the development of high LDL-C and hypertriglyceridemia. A cohort study in Japan found that individuals with higher baseline SUA levels were more likely to develop high LDL-C over a five-year period, suggesting that SUA could be a useful marker for identifying individuals at risk for dyslipidemia.
A large-scale survey in China revealed a high prevalence of dyslipidemia, with significant proportions of the population not meeting LDL-C targets, especially among those at high or very high risk for atherosclerotic cardiovascular diseases (ASCVD). This underscores the need for improved management strategies and adherence to lipid-lowering therapies.
The primary goal in managing high LDL-C is to reduce cardiovascular risk. Statins are the cornerstone of LDL-C lowering therapy, but additional treatments such as mipomersen, an apolipoprotein B synthesis inhibitor, have shown promise in patients with genetic conditions like homozygous familial hypercholesterolemia. Lifestyle modifications, including dietary changes and increased physical activity, are also crucial components of managing high LDL-C levels .
High LDL cholesterol is a significant risk factor for various cardiovascular and peripheral vascular diseases. Effective management through dietary modifications, lifestyle changes, and pharmacotherapy is essential to reduce the associated risks. Ongoing research continues to refine our understanding of LDL-C's role in disease and the best strategies for its management.
Most relevant research papers on this topic